Korro Bio, Inc.

NASDAQ:KRRO

Biotechnology

Healthcare
$12.44 +15.88%

+$1.76 today

Market cap
$170.75M
Beta
2.10
P/E (TTM)
-1.3
EPS (TTM)
-$9.79
52W Low $5.20High $55.89

Volume 0.16M

Average 0.15M

KRRO Free Cash Flow

Operating cash flow minus capital expenditures: cash available for debt repayment, dividends, and buybacks.

Korro Bio, Inc.NASDAQ: KRRO

Free Cash Flow · Q1 FY2026 · quarter ended Mar 2026

Free cash flow declines year over year

Q1 FY2026 free cash flow of $16.1M (cash outflow) fell 34.5% year over year, behind the -5.9% change in trailing-twelve-month free cash flow. Sequentially, it fell 9.5% from the prior quarter. Over 3 fiscal years it compounded at +10.3% a year.

Context

  • Free cash flow amounted to 1237.2% of revenue in FY2025, down 2196.4 pp from a year earlier.
  • Free cash flow grew in size in 3 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -34.5% toward the trailing-twelve-month pace of -5.9%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$16.1M-9.5% QoQ
Last fiscal yearDec 2025
-$79.08M+1.4% YoY
LTMMar 2026
-$70.6M-5.9% YoY
Free Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-34.5%——
1 year+1.4%——
3-year CAGR+10.3%——
5-year CAGR——
10-year CAGR——

Free Cash Flow history

USD · from the cash flow

Latest · FY2025
(79.08M) USD
Year-over-year change
-1.4%

Free Cash Flow vs competitors

How KRRO compares with its peers on the latest reported figures

  • KRRO's LTM Mar 2026 free cash flow of $70.6M is the 7th largest of the 11 companies compared; the peer median is $81.8M.
  • Its year-over-year change of -5.9% is the 8th highest of 9, against a peer median of +38.8%.
  • Free cash flow amounts to 1837.7% of revenue for KRRO, versus a peer median of 7126.6%.
KRRO Competitors Peer median
Free Cash Flow for KRRO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ANNXAnnexon, Inc.LTM Mar 2026$183.16M +30.9%+14.9%—
DBVTDBV Technologies S.A.LTM Mar 2026$151.54M +67.5%+29.0%—
LRMRLarimar Therapeutics, Inc.LTM Mar 2026$131.32M +50.2%+60.0%—
ENGNenGene Holdings Inc.LTM Apr 2026$111.39M +46.6%+78.4%—
AURAAura Biosciences, Inc.LTM Mar 2026$91.64M +14.5%+15.2%—
ALTAltimmune, Inc.LTM Mar 2026$71.97M -10.4%+2.5%199908.3%
KRROKorro Bio, Inc.LTM Mar 2026$70.6M -5.9%+10.3%1837.7%
SLNSilence Therapeutics plcLTM Mar 2026$65.67M —+2.7%7126.6%
ANROAlto Neuroscience, Inc.LTM Mar 2026$62.86M +14.6%+34.8%—
LBRXLB Pharmaceuticals Inc Common StockLTM Mar 2026$51.71M —+134.7%—
AMRNAmarin Corporation plcLTM Mar 2026$25.51M +182.6%—11.9%
Peer median (excluding KRRO) $81.8M+38.8%+29.0%7126.6%

Competitors are the stored peer set for KRRO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(21.96M)(58.03M)(81.17M)(83.58M)(117.26M)
Depreciation & Amortization1.6M2.51M3.63M3.57M3.79M
Deferred Income Tax0(145K)000
Stock-Based Compensation807K1.14M2.38M4.46M7.66M
Change in Working Capital904K(633K)4.28M13.59M(4.43M)
Accounts Receivables000(1.7M)727K
Inventory00000
Accounts Payables56K1.76M3.1M(1.34M)(2.31M)
Other Working Capital848K(2.39M)1.18M16.63M(2.84M)
Other Non-Cash Items(13.44M)1.51M3.6M1.89M31.68M
Operating Cash Flow(32.09M)(53.65M)(67.28M)(60.07M)(78.56M)
Capital Expenditures(4.45M)(5.21M)(7.84M)(17.9M)(518K)
Acquisitions (Net)00000
Purchases of Investments(35.07M)(37.21M)0(146.35M)(26.19M)
Sales of Investments053.49M19M40.9M70.7M
Other Investing Activities13K0000
Investing Cash Flow(39.5M)11.06M11.16M(123.35M)43.99M
Debt Repayment00000
Common Stock Issued28K62K117.25M67.39M685K
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(2K)(44K)25.05M1.97M0
Financing Cash Flow115.95M18K187.76M69.36M685K
Effect of Forex Changes000(4K)64K
Net Change in Cash44.35M(42.57M)131.64M(114.07M)(33.82M)
Free Cash Flow(36.54M)(58.86M)(75.12M)(77.98M)(79.08M)

Korro Bio, Inc.

NASDAQ:KRRO

Intrinsic Alpha fair value

Locked

Current Price

$12.44

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.